Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Steven Kaufman talks with ONdrugDelivery about the world of autoinjectors, looking at the current status quo in the industry, using Portal Instruments’ PRIME Nexus™ smart reusable electromechanical autoinjector as a lens to bring into focus how things have changed and where they might be going.
Steven Kaufman discusses the rapidly evolving world of drug delivery and the future of self-injection.
In this exclusive interview, Kaufman highlights the tipping point the industry is facing, driven by a crucial need for sustainability and cost-effectiveness in an era of billions of disposable devices. He sheds light on the next generation of solutions, focusing on the rise of smart, reusable, electromechanical autoinjectors.
Using Portal Instruments' PRIME Nexus™ device as a key example, Kaufman explains how innovative platforms are designed to handle challenges like high-viscosity formulations and varying fill volumes, all while significantly reducing environmental impact. Learn how devices that prioritize the entire value chain, from manufacturing to elegant design and digital health integration, are setting the new standard for improved patient adherence and successful combination product programs.
The full article can be found in ONdrugDelivery.
July 2021 - The world we live in and the technology we use are rapidly evolving. But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation.
November 2, 2021 - Jody was diagnosed with Scleritis, a serious eye disease that is often associated with an underlying autoimmune disorder. Fast forward to today, Jody has started taking weekly injections to ease her symptoms. We sat down with Jody to hear about her first at home injection.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Please fill out the details below and we will get back to you shortly.